Mutations associated with beta-thalassemia intermedia in Kuwait

Affiliations

01 January 2005

-

doi: 10.1159/000086186


Abstract

Objective: To identify the beta-globin gene mutations associated with beta-thalassemia (beta-thal) intermedia in Kuwait.

Subjects and methods: Eighteen patients from 13 unrelated families, mean age 12.7 +/- 8.1 years, range 4-31 years, were involved in the study. They did not require regular blood transfusion. Complete blood count and cation exchange high-performance liquid chromatography hemoglobin quantitation were carried out using standard techniques. Beta-thal mutations were identified with a combination of PCR amplification, allele- specific oligonucleotide hybridization or direct DNA sequencing. The patients were also screened for the alpha2-globin gene (-3.7 kb) deletion.

Results: Of the 13 families, 4 were homozygous for the IVS-I-II (G-->A) and 4 for the IVS-I-6 (T-->C) mutations, while 1 each was a compound heterozygote for the following mutation combinations: CD 8 (-AA) and -101 (C-->T); IVS-I-6 (T-->C) and CD 19 (A-->G); IVS-II-1 (G-->A) and -28 (A-->C); IVS-I-110 (G-->A) and deltabeta0 deletion. Therefore, homozygosity for two typically mild mutations (IVS-II-1 and IVS-I-6) accounted for 61% of the genotypes in our patients.

Conclusion: Our results indicate that screening should commence with these two common alleles in Kuwaiti patients presenting with beta-thal syndrome. Early identification of intermedia patients will avoid the complications following an unnecessary hypertransfusion program.


Similar articles

Spectrum of beta-globin gene mutations among thalassemia patients in the West Bank region of Palestine.

Darwish HM, El-Khatib FF, Ayesh S.Hemoglobin. 2005;29(2):119-32.PMID: 15921164

Study of beta-Thalassemia mutations using the polymerase chain reaction-amplification refractory mutation system and direct DNA sequencing techniques in a group of Egyptian Thalassemia patients.

El-Gawhary S, El-Shafie S, Niazi M, Aziz M, El-Beshlawy A.Hemoglobin. 2007;31(1):63-9. doi: 10.1080/03630260601057104.PMID: 17365006

Molecular basis of β-thalassemia in the United Arab Emirates.

Baysal E.Hemoglobin. 2011;35(5-6):581-8. doi: 10.3109/03630269.2011.634706.PMID: 22074124

[Molecular-genetic characteristics of alpha, beta and delta beta-thalassemias in 139 heterozygotes in 56 unrelated Czech and Slovak families (Priority description of 3 beta-thalassemia mutations, an extensive alpha-thalassemia 2 (18+ kb) deletion and a Swiss-type nondeletion hereditary persistence of hemoglobin F)].

Indrák K, Divoký V, Brabec V, Indráková J, Svobodová M, Huisman TH.Vnitr Lek. 1993 Oct;39(10):969-78.PMID: 7694425 Czech.

The molecular pathology of beta-thalassemia in Turkey: the Boğaziçi university experience.

Basak AN.Hemoglobin. 2007;31(2):233-41. doi: 10.1080/03630260701296735.PMID: 17486506


Cited by

Epidemiology of Thalassemia in Gulf Cooperation Council Countries: A Systematic Review.

Abu-Shaheen A, Heena H, Nofal A, Abdelmoety DA, Almatary A, Alsheef M, AlFayyad I.Biomed Res Int. 2020 Oct 28;2020:1509501. doi: 10.1155/2020/1509501. eCollection 2020.PMID: 33178817 Free PMC article.

beta-Thalassaemia Major in a Spanish Patient due to a Compound Heterozygosity for CD39 C --> T/-28 A --> C.

Gamarra S, Garcia-Effron G, Monteserin C, Lopez-Villar I, Gilsanz F, Martinez-Lopez J.Adv Hematol. 2009;2009:476342. doi: 10.1155/2009/476342. Epub 2009 Jul 28.PMID: 19960060 Free PMC article.


KMEL References